Stonewise

StoneWise, founded in 2018, is a leading technology company dedicated to AI-driven novel drug discovery, and became a JLABS Singapore member company in 2024. Based on the GPT/Transformer framework and integrated with geometric deep learning algorithms, StoneWise has exclusively built a small-molecule drug design platform with a multimodal AI 3D molecular generation large model as the core. The company offers products and services for early-stage drug discovery to over 100 pharmaceutical enterprises and research institutions worldwide, covering molecular generation and design, customized model training, compound screening, and other related solutions. Leveraging its core technologies and platform, StoneWise currently has multiple in-house R&D pipelines that have advanced to the clinical trial phase.